This study definitely confirms the role of LMP1 in EBV reactivation and further explores the mechanism by which EGCG inhibits EBV lytic replication.
Introduction
Epstein-Barr virus (EBV) is the first human tumor virus identified and known to be linked to several types of human malignancies, including gastric carcinoma (GC), Hodgkin's lymphoma (HL), Burkitt's lymphoma (BL), and nasopharyngeal carcinoma (NPC) (Souza et al., 2005) . In the host, EBV exhibits two alternative modes of infection, latent and lytic. In the latent infection, EBV only expresses a limited number of gene products such as latent membrane protein 1 (LMP1), LMP2A/2B, EBV nuclear antigens (EBNAs), and EBV-encoded small RNAs (EBERs). Studies indicated that the latent infection is a major cause of EBV-associated malignancies (Fiorina et al., 2014; Ko, 2015) . LMP1 is a classic EBV-encoded oncoprotein and plays a critical role in in vitro B cell transformation. As mimics of CD40, LMP1 functions as a constitutively activated tumor necrosis factor receptor (TNFR) to activate multiple signaling pathways, including NF-κB (Ma et al., 2011b) , PKC(Yan et al., 2007) , JAK/STAT (Wang et al., 2010) , MAPK(Li et al., 2007) , and PI3-K/Akt (Mori and Sairenji, 2006 ) that contribute to its oncogenic effects by affecting cellular proliferation and survival.
When stimulated by certain chemicals or biological reagents, the latently infected cells will enter into the lytic phase of EBV infection. During the lytic cycle, EBV briefly passes through three consecutive lytic stages, including the immediate early (IE), early (E), and late (L), and first transcribes the IE genes, BZLF1 and BRLF1, which encode two transactivators, Zta and Rta, respectively. The both proteins turn on the entire lytic viral cascade of gene expression, including BMRF1 and BALF5, which encode diffused early antigen (Ea-D) and DNA polymerase. Simultaneously, Zta also acts as a replication factor for EBV genomic DNA by binding the lytic origin of replication, oriLyt. After that, the late lytic genes express the viral structural proteins, followed by the viral genome encapsidation and production of mature virions. The transition from the viral latent to lytic cycle is called EBV reactivation, which is essential for virus production and transmission from host to host.
Ahsan et al. reported that LMP1 plays a critical role in virus production and transmission (Ahsan et al., 2005) . In this study, they provide the first evidence that LMP1 has a function in lytic reactivation. Based on the knowledge of mechanisms underlying EBV reactivation, LMP1 appears to facilitate EBV entry into the lytic cycle in a variety of ways. For instance, LMP1 leads to severe cellular stresses, which induce EBV lytic cycle initiation (Li et al., 2016) , such as hypoxia (Benders et al., 2009 ), oxidative stress (Papadopoulou et al., 2014) , and inflammation (Hannigan et al., 2011) . In addition, LMP1-induced S-phase-like microenvironment is essential for lytic viral replication (Sueur et al., 2014) . Thus, it is reasonable to speculate that LMP1 plays an important role in EBV reactivation. LMP1 has been shown to enhance transcriptional activity and stability of p53 by inducing phosphorylation of p53 at Ser15, Ser392, Ser20, and Thr81 through MAPKs in NPC cells (Li et al., 2007) . In an earlier study, Zhang et al. showed that p53 inhibits the ability of Zta to disrupt EBV latency (Zhang et al., 1994) . However, some recent studies indicate that p53 is a prerequisite for EBV reactivation by facilitating the expression of Zta (Chang et al., 2008; Chua et al., 2012) . Although it looks like controversial, these observations suggest the involvement of p53 in the regulation of EBV lytic cycle initiation.
Recently, EBV lytic replication has been shown to play an important role in carcinogenesis of several cancers. Clinical and epidemiological studies have revealed that individuals with elevated plasma EBV DNA load and antibody titers against the lytic viral capsid antigen (VCA) and early antigen (EA) have a high risk of EBV-induced malignancies (Jia and Qin, 2012; Liu et al., 2012) . Also, recurrent EBV reactivation causes tumorigenesis by inducing oncogenic cytokines and enhancing genomic instability (Fang et al., 2009) . Therefore, blocking EBV lytic replication is valuable for prevention and treatment of EBV-associated malignancies and helps to improve clinical outcome (Funch et al., 2005; Hong et al., 2005) . EGCG, the major active polyphenol in green tea, is an inhibitor of EBV lytic cascade (Chang et al., 2003) . Our previous study demonstrated that EGCG inhibits EBV spontaneous lytic replication through inactivation of MEK/ERK1/2 and PI3-K/Akt signaling (Liu et al., 2013) .
In this study, we have investigated the contribution of LMP1 to EBV reactivation in EBV-positive gastric carcinoma and B-cell lymphoma cell lines and demonstrated that the MAPK signaling pathways, including ERKs, p38, and JNKs, are required for EBV reactivation by LMP1. In p53 wide-type AGS-EBV cells, LMP1 induces EBV reactivation in a p53-dependent manner. Activation of c-Jun by LMP1 through JNKs is involved in reactivation of EBV in p53 mutant B95.8 cells. We have also demonstrated that EGCG inhibition of EBV lytic replication is involved in the repression of the LMP1-mediated MAPK signaling pathways.
Results

Detection of EBV-encoded products in cell lines and biopsies
To investigate the possible role of LMP1 in the EBV lytic cycle, we used the AGS-EBV gastric carcinoma cell line containing recombinant EBV which is permissive for EBV lytic replication. We also used the B95.8 cells, a well-established EBV lytically-infected cell line. As shown, LMP1 and the lytic proteins, Zta and Ea-D, were expressed in both AGS-EBV and B95.8 cells ( Figure 1A ). By using a quantitative real-time PCR, the EBV genome copies were detected at significant levels in both AGS-EBV cells (5.34×10 6 copies/μl) and B95.8 cells (6.27×10 6 copies/μl) ( Figure 1B ).
Detecting EBERs by in situ hybridization has been regarded as a standard of EBVpositive in EBV-associated tumors. Immunohistochemistry to detect LMP1, Zta, and Ea-D was performed on formalin-fixed, paraffin-embedded tissue from EBER positive gastric carcinoma and B lymphoma. Positive signal implies that LMP1 expression occurs in tumor cells as shown by nuclear and/or cytoplasm localization, and expressions of Zta and Ea-D occur as shown by nuclear localization in different cases. We observed LMP1-, BZLF1-, and BMRF1-positive cells within the gastric carcinoma and B lymphoma biopsies. We detected the expressions of LMP1, Zta, and Ea-D in all (100%) of the 10 patients with EBER-positive gastric carcinoma and in all (100%) of 14 patients with EBER-positive B lymphoma ( Figure 1C ).
These results suggest that EBV spontaneous lytic replication exists in both cell lines and biopsies of EBV-positive gastric carcinoma and B lymphoma. Moreover, EBV-encoded LMP1 is also detected in the both biopsies.
LMP1 promotes EBV reactivation in AGS-EBV and B95.8 cells.
Then, we tested whether LMP1 could induce EBV reactivation. The cells were transfected with a plasmid containing pSG5-LMP1 or a control pSG5 vector. We found that Zta and Ea-D were markedly upregulated and EBV genome copies were higher compared to controls (Figure 2A ). Next, knockdown of LMP1 by DZ1, a designed DNAzyme which specifically targets transcripts of LMP1, significantly reduced expression of Zta and Ea-D and decreased the numbers of EBV genome copy ( Figure 2B ).
MAPK signaling pathways are required for LMP1-induced EBV reactivation.
Mitogen-activated protein kinases (MAPKs), including extracellular signal regulated kinases (ERKs), p38, and c-Jun NH2-terminal kinases (JNKs), are strongly activated in response to variety of different cellular stimuli (Goswami et al., 2012; Satoh et al., 1999) . We found that phosphorylation levels of ERKs, p38, and JNKs were increased followed by LMP1 induction in AGS-EBV and B95.8 cells ( Figure   2C ). To determine whether MAPK signaling pathways is involved in LMP1-induced EBV reactivation, we first treated the cells with MAPK specific inhibitors. The inhibitors included PD98059, which is a specific inhibitor of MEK1 that acts by suppressing activation of ERK1/2, SB202190, a specific inhibitor of p38 kinase, and SP600125, an inhibitor of JNKs that exhibits a 300-fold greater selectivity for JNKs as compared to ERKs or p38. Pretreatment with PD98059, SB202190, or SP600125 markedly attenuated the expression of Zta and Ea-D in both cell models ( Figure 2D , E, and F). To further verify the requirement of MAPK signaling pathways for EBV lytic cycle initiation induced by LMP1, the cells were transfected with a plasmid containing pSG5-LMP1 or pSG5 control and simultaneously incubated with PD98059, SB202190, or/and Sp600125. A significant reduction in Zta and Ea-D expression was detected compared to untreated controls. When the three inhibitors were simultaneously added to cells transfected with pSG5-LMP1, the protein levels of Zta and Ea-D were lower compared to the levels in cells treated with each individual inhibitor and were similar to the negative control. As expected, the levels of EBV genomic copies were lower compared to the levels in cells transfected with pSG5-LMP1 ( Figure 2G , H).
Together, these observations above suggest that LMP1 promotes EBV reactivation and the activation of the downstream MAPK signaling pathways is required for LMP1-induced EBV reactivation.
LMP1 induces EBV reactivation in a p53-dependent manner in p53 wide-type
AGS-EBV cells.
P53 is an important downstream molecule of the MAPK signaling pathways. To examine the role of p53 in EBV lytic initiation, AGS-EBV and B95.8 cells were transfected with the plasmid expressing wide-type p53. We found that inducible p53 expression significantly increased the levels of Zta and Ea-D ( Figure 3A ). We further knocked down p53 by siRNA. The data showed that Zta and Ea-D were downregulated in AGS-EBV cells, but no significant changes were detected in B95.8 cells ( Figure 3B ). As p53 is mutant in B95.8 cell line (Farrell et al., 1991; Forte and Luftig, 2009; Li et al., 2008) , and there is no hot spot mutation of p53 in AGS-EBV cell line ( Supplementary Figure 1 ), suggesting that wild-type p53 may be critical for regulation of EBV reactivation. Moreover, inducible expression of p53 also increased numbers of EBV genomic copy ( Figure 3C ). Our results further showed that knockdown of p53 by siRNA counteracted LMP1-induced expressions of both Zta and Ea-D and EBV DNA replication in AGS-EBV cells ( Figure 3D , E). Next, we tested the effect of p53 on the activity of BZLF1 promoter (Zp) using a Zp/luciferase reporter system in combination with transfection of the plasmid expressing p53 in p53-null H1299 cells. As shown, p53 activated Zp in a dose dependent manner ( Figure 3F ). A ChIP assay showed that p53 could bind to the positions -221 to +12 of Zp in AGS-EBV cells ( Figure 3G ). Recently, studies have shown that p53 interacts with the universal transcription factor Sp1 to activate Zp(Chua et al., 2012) and is also known to interact with members of the SMAD family of transcription factors to enhance transcription from their downstream target genes (Overstreet et al., 2014) . By using a co-immunoprecipitation (Co-IP) assay, our results showed that the interactions 1 0 between p53 and Sp1 or SMAD2 were significantly enhanced after LMP1 induction ( Figure 3H ). Thus, LMP1 may improve the ability of p53 to recruit Sp1 and SMAD2 on sits of Zp, inducing Zta expression and thus EBV reactivation.
The results suggest that wide-type p53 induces Zta expression by binding to and activate Zp and that LMP1 enhances the ability of p53 to activate Zp via directly binding to Zp as well as through cooperation with Sp1, promoting Zta-mediated EBV reactivation in AGS-EBV cells.
Phosphorylation of p53 and c-Jun mediated by MAPKs are involved in
LMP1-induced EBV reactivation in AGS-EBV and B95.8 cells, respectively.
In a previous study, our group demonstrated that LMP1 induces phosphorylation of p53 through MAPKs in NPC cells (Li et al., 2007) . Phosphorylation of p53 at Ser15
by ERKs results in p53 for transactivation, phosphorylation of p53 at Ser392 by p38 regulates its oligomerization and affinity for sequence-specific DNA, and phosphorylation of p53 at Ser20 by JNKs is crucial for p53 stabilization. Here, inducible expression of LMP1 increased the levels of total p53, phosphorylated MAPKs, and phosphorylated p53 at Ser15, Ser20, and Ser392 in AGS-EBV cells ( Figure 4A ). After treatment with PD98059 and SB202190, phosphorylation of p53 at Ser15 and Ser392 was reduced as result of the inactivation of ERKs and p38, respectively, and no significant changes in p53 expression were detected, followed by the downregulation of Zta and Ea-D expression ( Figure 4B , C). P53 expression and phosphorylation of p53 at Ser20 were both decreased after inactivation of JNKs by 1 SP600125, followed by the downregulation of Zta and Ea-D expression ( Figure 4D ).
The results suggest that LMP1 regulates the transcriptional function and stability of p53 through MAPKs in AGS-EBV cells, implying that LMP1 enhances the ability of p53 to promote Zta-mediated EBV reactivation.
MAPKs is also shown to modify and activate many transcription factors of Zp, such as c-Jun, ATFs, and CREB (Kenney and Mertz, 2014; Li et al., 2016) . C-Jun is a component of the transcription factor activator protein-1 (AP-1) complex (Feng et al., 2007) , and its transcriptional activity is regulated by phosphorylation at Ser63 and Ser73 through JNKs (Morton et al., 2003) . In B95.8 cells, we found that the levels of phosphorylated JNKs and phosphorylated c-Jun at Ser63 and Ser73 were increased after LMP1 induction ( Figure 4E ). Furthermore, inactivation of JNKs mediated by SP600125 inhibited phosphorylation of c-Jun at Ser63 and Ser73, followed by the decreased expression of Zta and Ea-D ( Figure 4F ). The evidences indicate that activation of c-Jun by LMP1 through JNKs might be involved in reactivation of EBV in B95.8 cell line which has p53 mutation.
The mechanism by which LMP1 induces EBV reactivation in AGS-EBV and Figure 5 ).
EGCG inhibits EBV spontaneous lytic replication by suppressing
LMP1-midiated MAPK signaling pathways.
Our recent study demonstrated that EGCG inhibition of EBV spontaneous lytic infection involves repression of PI3-K/Akt and MEK/ERKs signaling pathways in EBV-positive NPC cells (Liu et al., 2013) . To further explore the mechanisms by which EGCG inhibits EBV reactivation, AGS-EBV and B95.8 cells were incubated with EGCG. Results showed that EGCG treatment significantly downregulated Zta and Ea-D expression ( Figure 6A ). Consistent with the results, RT-qPCR assay showed that transcripts of lytic genes, BZLF1 and BMRF1, were substantially attenuated by EGCG ( Figure 6B ). In addition, we detected a reduction in the number of EBV genome copies after EGCG treatment ( Figure 6C ). Flow cytometry analysis revealed that after treatment with EGCG, the percentage of cells expressing Zta decreased from 16.24 to 10.93% in AGS-EBV cells and from 17.51 to 5.79% in B95.8 cells.
Additionally, the percentage of cells expressing Ea-D decreased from 34.80 to 15.18% in AGS-EBV cells and from 27.67 to 14.77% in B95.8 cells ( Figure 6D ). These data confirm the inhibitory effects of EGCG on EBV spontaneous lytic replication in the both cell lines.
Furthermore, EGCG was shown to reduce LMP1 expression and phosphorylated ERKs, p38, and JNKs in a dose-dependent manner, followed by downregulation of Zta and Ea-D expression ( Figure 6E , F). In AGS-EBV cells, total p53 and phosphorylated p53 were significantly downregulated by EGCG in a dose-dependent manner ( Figure 6E ). Moreover, a co-IP assay showed that EGCG inhibited the ability Figure 1A and 1C ). Therefore, LMP1 may be involved in initiation of the EBV lytic cycle. In this study, we showed that LMP1 contributes to EBV reactivation in both AGS-EBV and B95.8 cells ( Figure 2 ). Furthermore, our results showed that the MAPK specific inhibitors synergistically counteracted LMP1 induction of lytic protein expression ( Figure 2G ), indicating that the MAPK signaling pathways are required for LMP1-induced EBV reactivation.
P53 is deemed to be involved in regulation of EBV reactivation, our results confirmed that p53 contributes to EBV reactivation, and wide-type p53 is critical for the effect (Figure 3A and 3B). And we further found that p53 binds to and activates BZLF1 promoter ( Figure 3G ). Besides, we also demonstrated that p53 binds to and activate another IE gene promoter, BRLF1 promoter (positions -442 to -2) (Supplementary Figure 2) . The evidence suggests that p53 may induce expression of Zta and Rta by binding to and activating Zp/Rp, amplifying its lytic-inducing effects on EBV lytic cycle initiation.
Li et al. showed that phosphorylation of p53 at Ser15 by ERKs results in p53 for transactivation, phosphorylation of p53 at Ser392 by p38 regulates its oligomerization and affinity for sequence-specific DNA, and phosphorylation of p53 at Ser20 by JNKs is known to be crucial for p53 stabilization (Li et al., 2007) . In AGS-EBV cells, LMP1 was shown to induce phosphorylation of p53 at Ser15, Ser392, and Ser20 and increase p53 protein level through MAPKs ( Figure 4A , B, C, and D), which suggest that LMP1 might regulate the ability of p53 to bind to and activate Zp. P53 is shown to promote the transcription from Zp via interaction with Sp1(Chua et al., 2012). In addition, p53 cooperates with SMADs to transactivate downstream target genes (Cordenonsi et al., 2003) . And we detected the enhanced interactions between p53 and transcription factors Sp1 or SMAD2 after LMP1 induction ( Figure 3H ), suggesting that phosphorylation of p53 by LMP1 also promotes p53 enrichment and thus improves the ability of p53 to recruit Sp1 and SMAD2 on sites of Zp. However, it needs to be investigated whether the cooperation of p53 with SMAD2 contributes to EBV reactivation. Furthermore, we found that knockdown of p53 by siRNA significantly counteracts LMP1-induced expression of lytic proteins ( Figure 3D ).
These results demonstrate that LMP1 contributes to EBV lytic cycle initiation in a In our previous study, we have demonstrated that EGCG blocks EBV spontaneous lytic replication by suppressing the activation of MEK/ERK1/2 and PI3-K/Akt signaling in NPC cells (Liu et al., 2013) . Here, we further found that EGCG inhibition of EBV lytic replication involves blocking LMP1-mediated MAPK signaling pathways ( Figure 6 
Co-Immunoprecipitation (Co-IP) Assay
Immunoprecipitation was performed with AGS-EBV cells that were transfected with a plasmid containing the pSG5 vector or pSG5-LMP1. After 72 h, cell lysates (500 μ g) prepared with IP lysis buffer were incubated with 20 μ l protein A sepharose beads (Sigma, St. Louis, MO) for 2 h at 4 °C on a rotating rocker and centrifuged for 10 min at 2000 rpm to preclear. The recovered supernatant fraction was incubated 1 with anti-p53 (sc-126 X, Santa Cruz, CA) in the presence of 1× protease inhibitors at 4°C overnight on a rotating rocker. Then 40 μ l of protein A sepharose beads were added, and the incubation was continued for 2 h at 4°C on a rotating rocker. The immunocomplexes bound to sepharose beads were recovered by a brief centrifugation followed by 3 washes with cold 1× PBS. The harvested beads were resuspended in 20 μ l of 5× SDS PAGE sample buffer and boiled for 5 min to release the bound proteins.
A 50 μ g cell lysate was used as an input control. The samples were analyzed by Western blotting.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed essentially as described by Shi Y (Shi et al., 2012) .
Cells (5×10 6 ) were cross-linked with 37% formaldehyde (1% final volume, Sigma).
Cross-linking was stopped by the addition of 1/10 volume of 1.25 M glycine. Then the cells were harvested and disrupted using cell lysis buffer. The lysates containing chromatin were sonicated to obtain DNA fragments with an average length of <500 bp. After centrifugation, the protein concentration of the lysates was determined by the Bradford assay using the Pierce TM BCA Protein Assay Reagent (Thermo, USA).
The protein-chromatin (300 μ g) complexes were used for each immunoprecipitation.
The antibody-protein complexes were captured with pre-blocked protein G dynabeads (Invitrogen, Carlsbad, CA). Immunoprecipitation DNA was analyzed by PCR for the quantification of DNA sequences and the recovered DNA was amplified by PCR.
ChIP primers are detailed in Supplementary table 1 .
DNA extraction and quantification of EBV copy number
DNA was extracted from each sample (2 ×10 6 cells) using the QIAamp 
Transfection and luciferase assay
The cells were seeded into 24-well plates at the appropriate density and allowed to adhere overnight. When cells reached 70~90% confluence, various amounts of pEGFP-C3-p53 were co-transfected respectively with pZp-luc or pGL3-basic and the pRL-TK internal control into cells using the Lipofectamine 
Statistical analysis
Data are expressed as mean values ± S.D. and differences between various groups were determined using the Student's t-test. A value of p<0.05 was considered statistically significant. Incubation with vehicle but no primary antibody followed by incubation with the secondary antibody was used as a negative control. AGS-EBV and B95.8 cells were starved in 0.1% FBS HAM'S/F-12 or RPMI medium 1640 for 24 h and then treated with different concentrations of EGCG as indicated or vehicle (DMSO) for 24h. (E and F) Cell lysates were harvested and analyzed for LMP1, total and phosphorylated MAPKs, and lytic proteins using western blot analysis. Effects of EGCG on the levels of total and phosphorylated p53 were also determined in AGS-EBV cells. β -Actin was used as an internal control.
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